Mark Corrigan

Dr. Corrigan has served on the board of directors since June 2, 2021. Dr. Corrigan is a highly successful pharmaceutical executive with 30 years of industry experience. Dr. Corrigan co-founded Tremeau Pharmaceuticals, Inc. in 2016. From 2010 to 2014, he served as Director, President and Chief Executive Officer of Zalicus, Inc. prior to their merger with Epirus Biopharmaceuticals in July 2014. Previously, Dr. Corrigan was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc. He also spent 10 years with Pharmacia & Upjohn. Where he served as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the pharmaceutical industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department. Dr. Corrigan currently serves as Chairman of the Board of Exacis Therapeutics and served on the board of directors of Cubist Pharmaceuticals, where he chaired the Scientific Committee, and of Avanir Pharmaceuticals, Inc. where he also served as their chair of the SAC. Dr. Corrigan holds a Bachelor of Science from the University of Virginia, as well as an MD from the University of Virginia School of Medicine. We believe Dr. Corrigan is qualified to serve as a director due to his extensive experience in the pharmaceutical industry, his service on other boards of directors and his educational background.